Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris

• ClinicalTrials.gov Identifier: NCT00558831
• Recruitment Status: Completed
• First Posted: November 15, 2007
• Results First Posted: November 22, 2010
• Last Update Posted: September 26, 2017
• Sponsor: Northwestern University
• Information provided by (Responsible Party): Amy Paller, Northwestern University

Study Description

Brief Summary:

The purpose of this study is to compare the efficacy of a benzoyl peroxide 2.5% cream formulation plus a moisturizing lotion versus benzoyl peroxide 2.5% cream alone for the treatment of acne vulgaris.

Condition or disease	Intervention/treatment	Phase
Acne Vulgaris	Drug: Benzoyl Peroxide; Drug: Moisturizing Lotion	Not Applicable

Detailed Description:

The purpose of this study is to compare the safety and efficacy of a benzoyl peroxide 2.5% cream formulation plus a moisturizing lotion versus benzoyl peroxide 2.5% cream alone for mild to moderate acne vulgaris.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 11 participants
• Allocation: Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Split-face, Paired-comparison Pilot Study to Evaluate the Safety and Efficacy of Topical Benzoyl Peroxide 2.5% Cream Alone Versus Benzoyl Peroxide 2.5% Cream Plus Moisturizing Lotion for Mild to Moderate Acne Vulgaris
• Study Start Date: October 2007
• Actual Primary Completion Date: January 2008
• Actual Study Completion Date: January 2008

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Benzoyl Peroxide; Benzoyl Peroxide (BP) 2.5%	Drug: Benzoyl Peroxide; Benzoyl Peroxide 2.5%
Active Comparator: Benzoyl Peroxide plus moisturizing lotion; Benzyol Peroxide 2.5% plus moisturizing lotion	Drug: Benzoyl Peroxide; Benzoyl Peroxide 2.5%; Drug: Moisturizing Lotion

Outcome Measures

Primary Outcome Measures :

1. Subject Reported Change From Baseline Scale [ Time Frame: baseline and 1 month ]

   -1=worse 0=unchanged

   • 1=mild improvement
   • 2=moderate improvement
   • 3=clear

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 35 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Healthy male or female subjects who are 18 to 35 years of age.
2. Subjects are in good health and are free of any other facial skin disorders that may interfere with acne study assessments.
3. Subjects have the willingness and ability to understand and provide informed assent/consent to participate in the study and are able to communicate with the investigator. Subjects are willing and able to follow all study directions and to commit to all follow-up visits for the duration of the study. In addition, subjects must be willing to accept the restrictions of the study.
4. A minimum of 2 but no more than 30 inflammatory lesions (papules and pustules), relatively symmetrical in appearance on both sides of the face and a minimum of 2 but not more than 100 non-inflammatory lesions (open comedones and closed comedones) relatively symmetrical in appearance on both sides of the face.
5. Ongoing oral medications (other than those specifically for acne) are acceptable provided subjects are on a stable regimen throughout the study and provided the medications are determined likely to not interfere with study assessments.
6. Subjects will not use medicated cosmetics and/or soaps (including soaps containing antibacterial agents such as benzoyl peroxide, keratolytic agents such as salicylic acid, skin fresheners/astringents or aftershave lotions) for the duration of the study.
7. Subjects who agree not use any other acne treatment (including prescription and non-prescription medications) on the test site for the duration of the study.
8. Subjects who agree not to change facial cosmetic products during the study.
9. Subjects who agree to only use sunscreen/sunblock agents that are labeled as non-comedogenic.

Exclusion Criteria:

1. Subjects or parents of subjects who are unable to understand the protocol or to give informed consent/assent.
2. Subjects with mental illness.
3. Subjects with no inflammatory acne.
4. Subjects with any acne cysts or nodules.
5. Subjects with acne conglobata, acne fulminans, secondary acne (e.g. Chloracne, drug-induced acne), or any acne requiring systemic treatment.
6. Subjects with excessive facial hair that may interfere with study assessments.
7. Subjects with other facial skin disorders that may interfere with study assessments.
8. Subjects with a history of skin cancer or actinic keratosis.
9. Subjects who have used tanning devices within one week prior to baseline study visit.
10. Subjects who have applied any topical products (e.g. emollients, sunscreens) or any cosmetics to the face at least one hour prior to study assessments.
11. Use of hormonal oral contraceptives for acne control or for less than 6 months prior to study baseline.
12. Subjects with known allergies, a history of, or sensitive to salicylic acid, benzoyl peroxide or any of the test article components.
13. Subjects using topical or systemic medication within 14 days before the study entry, which could interfere with study assessments. This includes but is not limited to the following: anti-inflammatory drugs (e.g. topical and systemic corticosteroids and systemic antihistamines), anti-acne drugs, topical and oral retinoids, topical antibacterial agents to the face, and any immunosuppressive drugs. Ongoing oral medications not expected to interfere with study assessments are allowed if the subject is on a stable regimen.
14. Subjects who are currently enrolled in another clinical investigation or have been enrolled in an acne trial within a period of 30 days prior to enrollment in this study.
15. Subjects who are pregnant or nursing.
16. Subjects who require electrolysis, waxing, or depilatories on the face during conduct of the study.
17. Subjects viewed by the investigator as not being able to complete the study.

Contacts and Locations

Locations

United States, Illinois

Northwestern University Department of Dermatology

Chicago, Illinois, United States, 60611

Sponsors and Collaborators

Northwestern University

Investigators

• Principal Investigator: Amy Paller, MD; Northwestern University

More Information

• Responsible Party: Amy Paller, Principle Investigator, Northwestern University
• ClinicalTrials.gov Identifier: NCT00558831
• Other Study ID Numbers: STU1884
• First Posted: November 15, 2007
• Results First Posted: November 22, 2010
• Last Update Posted: September 26, 2017
• Last Verified: August 2017

Keywords provided by Amy Paller, Northwestern University:

Acne

Additional relevant MeSH terms:

Acne Vulgaris; Acneiform Eruptions; Skin Diseases; Sebaceous Gland Diseases; Benzoyl Peroxide; Dermatologic Agents